Company Overview
About Nuvig Therapeutics
Nuvig Therapeutics is a privately held biotechnology company developing next-generation immunomodulatory therapies for patients with chronic inflammatory and autoimmune diseases. Its lead candidate, NVG-2089, is a first-in-class recombinant Fc fragment engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that restores immune balance without the broad immunosuppression associated with existing treatments.
Business Model & Competitive Advantage
In December 2024, Nuvig announced a $161 million Series B financing co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners, with participation from B Capital, Leaps by Bayer, Bristol Myers Squibb, Novo Holdings, and others. This followed a $47 million Series A led by Novo Holdings in May 2022. NVG-2089 is advancing into Phase 2 clinical development for chronic inflammatory demyelinating polyneuropathy (CIDP) and additional undisclosed autoimmune indications.
Competitive Landscape 2025–2026
Nuvig''s platform aims to preserve normal immune function while achieving durable disease control — a key differentiation from corticosteroids, IVIg, and other broad immunosuppressants used in current autoimmune treatment protocols.
Key Differentiators
Strong Challenger
Nuvig Therapeutics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Compare Nuvig Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Nuvig Therapeutics? Verify your company email to claim this profile and keep its description, products, and FAQs up to date.
Claim Nuvig Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Nuvig Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →